Evidence map›Paper›PMID 22822001›Full record

ArticleBlood2012

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

Sara Ali, Ruhena Sergeant, Stephen G O'Brien, Letizia Foroni, Corinne Hedgley, Gareth Gerrard, Dragana Milojkovic, Kate Stringaris, Ahmad Khoder, Abdullah Alsuliman and 8 more

Open access · bronzeAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Immunology and immunotherapy of chronic myeloid leukemia.Current hematologic malignancy reports · 2014
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Sara Ali
Ruhena Sergeant
Stephen G O'Brien
Letizia Foroni
Corinne Hedgley
Gareth Gerrard
Dragana Milojkovic
Kate Stringaris
Ahmad Khoder
Abdullah Alsuliman
Maria Gilleece
Ian H Gabriel
Nichola Cooper
John M Goldman
Jane F Apperley
Richard E Clark
David Marin
Katayoun Rezvani
Imperial College London · GBLeeds General Infirmary · GBNewcastle University · GBUniversity of Liverpool · GB

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Cancer Research UK 10411Department of Health NF-SI-0611-10275
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DasatinibHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositivePharmacogeneticsPrognosisProtein Kinase InhibitorsPyrimidinesReceptors, KIRThiazolesDasatinibKIR2DS1 protein, humanProtein Kinase InhibitorsPyrimidinesReceptors, KIRThiazoles

Identifiers

PMID22822001
PMCPMC6143148
OpenAlexW2009579938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.